• Incannex began screening participants in its DReAMzz Phase 2 dose-confirmation trial of IHL-42X for obstructive sleep apnea.
• First sites are screening now; additional sites are expected to start as approvals are secured.
• IHL-42X holds FDA Fast Track designation, supporting a potentially expedited regulatory path ahead of planned Phase III development.
• Incannex cited prior Phase 2 results showing up to 83% reduction in apnea-hypopnea index, with improvements in patient-reported outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-080622), on July 23, 2026, and is solely responsible for the information contained therein.